Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Siemens’ New Biograph mCT PET-CT System Enables Greater Diagnostic Certainty

28.11.2011
The new PET-CT scanner offers accurate, reproducible quantification in molecular imaging, for results that redefine clinical decision-making

At the 97th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), November 27 to December 2 in Chicago, USA, Siemens Healthcare introduced the next-generation Biograph mCT, its positron emission tomography-computed tomography (PET-CT) scanner that enables precise measurement of metabolic processes and data quantification, including the assessment of neurological disease and cancerous tissue, as well as cardiac blood flow (perfusion). Technological innovations and intelligent software solutions within the new PET-CT result in quantitative assessments that are accurate and consistent. Siemens presents with the new Biograph mCT another paradigm in PET-CT to further strengthen the company’s innovative power and competitiveness within the recently introduced global initiative “Agenda 2013”.


“By bringing accuracy and reproducibility to quantification in PET, we can more precisely characterize cancer lesions, allowing for better staging and monitoring of the change in activity over time for more accurate assessment of treatment response”, said Jerry Froelich, MD, FACR, Loken Professor of Radiological Sciences and head of molecular imaging and nuclear medicine at the University of Minnesota, Minneapolis. “In cardiology, being able to measure absolute myocardial blood flow allows for accurate assessment of multi-vessel disease.

In neurology, the potential is huge. The ability to noninvasively assess the brain can improve the diagnosis and therefore management of patients presenting signs of Alzheimer's disease.” Siemens incorporated this clinical requirement in the new Biograph mCT to support physicians in treating many oncological, cardiological and neurological diseases – not only through earlier, more exact diagnosis, but also in therapy planning and precise monitoring of disease progression.

The additional information provided will help enable physicians to make decisions with high certainty and initiate more patient-tailored therapies. The level of measurement and quantification to be offered by the new Biograph mCT has special significance for the diagnosis of neurodegenerative diseases, such as dementia.

With the latest Biograph mCT and potential new PET biomarkers1, reliable imaging of beta-amyloid plaque in the brain may be possible, providing additional information to aid in the diagnosis of dementia, potentially slowing disease progression through earlier care. The most frequently diagnosed form of dementia is Alzheimer’s disease, which currently affects an estimated 35.6 million people worldwide, with predictions of as many as 115.4 million patients having the disease by 2050.2

Technical Innovations

With conventional technology, clinicians face the issue of variability in quantitative results due to software and hardware challenges. Intelligently engineered to overcome these technical and procedural obstacles, the new Biograph mCT is designed to offer accurate and reproducible quantification in PET•CT imaging by ensuring that each element of the imaging chain is optimized – with an emphasis on the finest volumetric image resolution on the market3, daily system calibration, accuracy of attenuation correction using automated co-registration algorithms and more automated, user-independent and reproducible SUV calculation methods for daily clinical practice.

The new Biograph mCT incorporates the Siemens unique OptisoHD (High-Definition) Detector System, which will feature a fine volumetric resolution4 of only 87 mm3. Other innovative technologies include Time of Flight (TOF) and HD (High-Definition) PET, ensuring fast, precise images with minimum radiation dose. With Siemens Quanti•QC, daily system normalization can be performed overnight, calibrating and tuning the system to precisely the right specifications, facilitating consistent and optimal performance, day after day.

SMART (Siemens Molecular & Anatomical Registration Technologies) address the traditional problem of inherent scanner drift and inaccurate attenuation correction through misregistration of anatomical and functional images.

To facilitate accurate attenuation correction and reliable quantitative measurements, the new Biograph mCT will feature a unique patient handling system designed to virtually eliminates differential deflection, as well as Auto Cardiac Registration that automatically aligns CT and PET heart images and reduces variability between users. SMART also offers a new form of attenuation correction for neurological images that no longer requires CT data.5

Advanced syngo clinical applications provide essential tools to obtain quantifiable measurements in neurology, cardiology and oncology imaging. SUVpeak, new in the syngo.via oncology engine, provides consistent and reproducible quantitative assessments of hot spots. Myocardial Blood Flow (MBF) can be used as an absolute quantification method to assess balanced disease in all areas of the heart. And an exciting quantitative tool in neurology, the syngo.PET Neuro6 applications, automatically registers brain data to a normals database to assist in the assessment of neurological disorders.

The new Biograph mCT is currently under review by the FDA.

Preparing for a Changing Healthcare Market

Agenda 2013 is a global initiative to further strengthen Healthcare Sector's innovative power and competitiveness. Four fields of action have been defined: Innovation, Competitiveness, Regional Footprint, and People Development, with specific measures to be implemented over the next two years.

The here mentioned product/features are not commercially available. Due to regulatory reasons, its future availability in any country cannot be guaranteed. Please contact your local Siemens organization for further details. The outcomes achieved by the Siemens customers described herein were achieved in the customer's unique setting. Since there is no "typical" hospital and many variables exist, e.g., hospital size, case mix, level of IT adoption, there can be no guarantee that others will achieve the same results.

The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimizing clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 51,000 employees worldwide and operates around the world. In fiscal year 2011 (to September 30), the Sector posted revenue of 12.5 billion euros and profit of around 1.3 billion euros.

Bianca Braun | Siemens Healthcare
Further information:
http://www.siemens.com/healthcare

More articles from Medical Engineering:

nachricht Medical gamma-ray camera is now palm-sized
23.05.2017 | Waseda University

nachricht Computer accurately identifies and delineates breast cancers on digital tissue slides
11.05.2017 | Case Western Reserve University

All articles from Medical Engineering >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Strathclyde-led research develops world's highest gain high-power laser amplifier

The world's highest gain high power laser amplifier - by many orders of magnitude - has been developed in research led at the University of Strathclyde.

The researchers demonstrated the feasibility of using plasma to amplify short laser pulses of picojoule-level energy up to 100 millijoules, which is a 'gain'...

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

New insights into the ancestors of all complex life

29.05.2017 | Earth Sciences

New photocatalyst speeds up the conversion of carbon dioxide into chemical resources

29.05.2017 | Life Sciences

NASA's SDO sees partial eclipse in space

29.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>